Encaleret
Phase 3Small molecule
Encaleret is one of 4 small molecule programs targeting Autosomal Dominant Hypocalcemia (ADH). It is currently in Phase 3.
2
Indications
5
Total Trials
3
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
3 competitors in Hypocalcemia
#DrugCompanyPhaseTrials
1Calciferol
Jazz PharmaceuticalsApproved
Zemplar
AbbVieApproved
Encaleret
CCalcilytix Therapeutics, Inc., a BridgeBio company
Phase 3
Tums
OtsukaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypocalcemia2 trials
Hypoparathyroidism1 trial
Autosomal Dominant Hypocalcemia (ADH)1 trial
CALIBRATE: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Active, not recruiting·CCalcilytix Therapeutics, Inc., a BridgeBio company·Phase 3·NCT05680818·67 enrolled
Unspecified1 trial
PTH-independent Effects of Encaleret
Completed·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT05735015·13 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Encaleret. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details